EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY 4.0

Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial

Arild Opheim, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli, Pia S Kloster, Lars Thore Fadnes, Nikolaj Kunøe, Zhanna Gaulen, Lars Tanum

Contemporary Clinical Trials · 2023

DOI: 10.1016/j.cct.2023.107360 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Contemporary Clinical Trials, 2023. Verfasst von Arild Opheim und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Addiction Medicine, Haukeland University Hospital, Norway; Institute of Global Public Health and Primary Care, University of Bergen, No…. Hauptthemen laut MEDLINE: Opioid-Related Disorders, Buprenorphine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Research Council of Norway.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: First study to assess any compensatory increase in use of non-opioid illicit substances and alcohol in opioid dependent patients randomized to treatment with extended-release naltrexone (XR-NTX) or buprenorphine-naloxone (BP-NLX) and in longer term treatment with extended-release naltrexone. METHOD: A multicenter, outpatient, open-label randomized clinical trial where patients received intramuscular extended-release naltrexone hydrochloride, 380 mg/month, or daily sublingual buprenorphine-naloxone 8-24/2-6 mg for 12 weeks, and an option to continue with extended-release naltrexone for an additional 36 week follow-up. The study was conducted at five urban addiction clinics and detoxification units in Norway between November 2012, and July 2016. RESULTS: Among the 143 patients, 106 men and 37 women, there were no significant differences between those randomized to XR-NTX or BP-NLX in the risk of first relapse to alcohol (HR 1.31; 0.68-2.53), amphetamines (HR 0.88; 0.43-1.80), benzodiazepines (HR 1.24; 0.74-2.09) or cannabis (HR 1.55; 0.83-2.89). Also in the 36-week (12-48 weeks) follow-up period we found no significant differences between patients continuing with XR-NTX compared to those switching to XR-NTX after the randomized period in risk of first relapse to any non-opioid substance. In both study periods, the mean time in the study were longer among those relapsing to non-opioid addictive substances than those who did not. There was no significant association between first relapse to illicit opioids and first relapse to non-opioid addictive substances. CONCLUSION: There was no increase in the risk of relapse to non-opioid addictive substances neither in short term nor longer-term treatment with extended-release naltrexone. Trial registrationclinicaltrials.gov Identifier: NCT01717963.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opioid-Related DisordersBuprenorphineMaleHumansFemaleNarcotic AntagonistsNaltrexoneBuprenorphine, Naloxone Drug CombinationAnalgesics, OpioidChronic DiseaseRecurrenceDelayed-Action PreparationsInjections, Intramuscular

Stichwörter der Autor:innen

Buprenorphine-naloxoneExtended-release naltrexoneOpioid dependenceRelapse to non-opioid addictive substances

Substanzen

Narcotic AntagonistsNaltrexoneBuprenorphine, Naloxone Drug CombinationAnalgesics, OpioidBuprenorphineDelayed-Action Preparations

Autor:innen und Institutionen

  • Department of Addiction Medicine, Haukeland University Hospital, Norway; Institute of Global Public Health and Primary Care, University of Bergen, Norway. Electronic address: arild.opheim@helse-bergen.no.
  • Institute of Clinical Medicine, Campus Ahus, University of Oslo, P.O.Box 1171, 0318 Blindern, Norway; Health Services Research Unit, Akershus University Hospital, P.O. Box 1000, 1478 Lorenskog, Norway.
  • Norwegian Centre for Addiction Research, University of Oslo, 0315 Oslo, Norway,; Department of Research and Development in Mental Health Services, Akershus University Hospital, 1478 Lorenskog, Norway; Vestfold Hospital…
  • Department of Addiction Medicine, Haukeland University Hospital, Norway.
  • Department of Addiction Medicine, Haukeland University Hospital, Norway; Institute of Global Public Health and Primary Care, University of Bergen, Norway.
  • Lovisenberg Diaconal Hospital, P.O. Box 4970, 0440 Oslo, Norway.

Förderung

  • Research Council of Norway

Zitieren

APA

Opheim, A., Benth, J. Š., Solli, K. K., Kloster, P. S., Fadnes, L. T., Kunøe, N., Gaulen, Z., & Tanum, L. (2023). Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial. Contemporary Clinical Trials. https://doi.org/10.1016/j.cct.2023.107360

Vancouver

Opheim A, Benth JŠ, Solli KK, Kloster PS, Fadnes LT, Kunøe N, et al. Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial. Contemporary Clinical Trials. 2023. doi:10.1016/j.cct.2023.107360

BibTeX
@article{Opheim2023,
  author = {Opheim, Arild and Benth, Jūratė Šaltytė and Solli, Kristin Klemmetsby and Kloster, Pia S and Fadnes, Lars Thore and Kunøe, Nikolaj and Gaulen, Zhanna and Tanum, Lars},
  title = {Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial},
  journal = {Contemporary Clinical Trials},
  year = {2023},
  doi = {10.1016/j.cct.2023.107360}
}
Kostenlos starten →